FLUCON 0.1 %
0.1 % · eye drops · bottle de 3 ml
fluorométholoneReference dated : 2026-06-02. Confirm price and availability with a pharmacist.
Public price
21,10 MAD
Laboratory
SOTHEMA
Composition and presentation
FLUCON 0.1 % — fluorométholone. Listed presentation: 0.1 % · Collyre · Flacon de 3 ml.
Full clinical reference
Additional sections are available in French. Read the original document; the information concerns the French reference product.
Uses
· Conjunctivo-palpebral allergic conditions,
· Keratitis,
· Anterior uveitis,
· Post-operative inflammatory reactions,
· Inflammatory state of the eyeball associated with glaucoma, due to the low glaucomatogenic action of fluorometholone.
Interactions
No interaction study has been conducted.
Concomitant use of topical corticosteroids and topical NSAIDs may increase the risk of corneal healing problems.
Driving
FLUCON, eye drops has no effect or a negligible effect on the ability to drive vehicles and use machines.
Transient blurred vision or other visual disturbances may diminish the ability to drive vehicles or use machines. In case of blurred vision occurring during instillation, the patient must wait until their vision becomes normal again before driving a vehicle or using a machine.
Adverse effects
The following adverse effects are from post-marketing surveillance and have been identified following administration of FLUCON, eye drops via spontaneous case reports and literature. The frequencies cannot be estimated from the available data. Within each organ system class, adverse effects are presented in descending order of severity.
| Organ system classes | Adverse effects |
| Ocular disorders | Frequency unknown: increased intraocular pressure, eye pain, ocular discomfort, sensation of a foreign body in the eyes, increased tearing, blurred vision (see section 4.4). Uncommon (≥ 1/1000 to ≤1/100): irritation, hyperemia, transient blurred vision after instillation of the product. Rare (≥1/10000 to <1/1000): subcapsular cataract, glaucoma, reduced visual acuity, ocular pruritus. Very rare (<1/10000): corneal perforation |
| Gastrointestinal disorders | Frequency unknown: dysgeusia |
| Infections and infestations | Rare (≥1/10000 to <1/1000): ocular infection (exacerbation or secondary) |
| Immune system disorders | Rare (≥1/10000 to <1/1000): allergy |
| Nervous system disorders | Rare (≥1/10000 to <1/1000): visual field alteration (in relation to glaucoma) |
| General disorders and administration site abnormalities | Rare (≥1/10000 to <1/1000): delayed healing |
| Investigations | Uncommon (≥ 1/1000 to ≤1/100): increased intraocular pressure |
Description of adverse effects
Prolonged use of topical ophthalmic corticosteroids may lead to increased intraocular pressure with optic nerve damage, decreased visual acuity and visual field disorders, formation of posterior subcapsular cataract and delayed healing (see section 4.4).
The development of secondary infections has occurred after the use of corticosteroids (see section 4.4).
In pathologies causing thinning of the cornea or sclera, perforations have been reported during the use of local corticosteroids (see section 4.4).
A few rare cases of corneal calcification have been reported in association with the use of drops containing phosphates in certain patients with severely damaged corneas.
Reporting of suspected adverse effects
Reporting of suspected adverse effects after authorisation of the medicinal product is important. It allows continuous monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals report any suspected adverse effect via the national reporting system: French National Agency for Medicines and Health Products Safety (ANSM) and the network of Regional Pharmacovigilance Centres - Website: https://signalement.social-sante.gouv.fr/ .
Hospital price
13,20 MAD
ATC code
C05AA06
Type
Originator
References and update dates
Historical reference; confirm the price with a pharmacist.
This information is informational and must be confirmed by a pharmacist or doctor. Do not change medicine or dosage based only on this page.
Price history
Reference price recorded since 2026-06-02: 21,10 MAD
Same ingredient, strength and form
This grouping does not establish interchangeability.
Other strengths and forms
Routes and instructions may differ.